The way we live, work, and interact is constantly being reshaped by technology, including how we research, produce, test, and handle data in the life sciences.
We gathered top speakers from across the life sciences and digital health sectors for our annual summit, Breakthrough, to exchange perspectives on how the industry is preparing for the future.
Two days of conversation on the technology, ideas, and trends driving the next generation of life sciences took place during our virtual conference.
Pharma executives provided their own thoughts on the life science business, as well as achievements in clinical development, patient safety, and regulatory affairs.
The ability of artificial intelligence (AI) and automation to move life sciences into a new age is a recurring issue.
Driving change through enterprise automation
Intelligent solutions are automating routine tasks and speeding up the pace of innovation for R&D teams that have previously struggled with inefficient and time-consuming human processes.
According to our State of the Industry Report for 2021, the majority of the life sciences industry (83 percent) now uses some level of automation in their R&D operations.
One of the primary areas pushing increased automation usage is pharmacovigilance, which will continue to expand within global safety activities.
“Intelligent automation became an unambiguous driver for this transition, causing fundamental and structural changes in how businesses understood and managed alterations in market situations,” says Priyank Agarwal, head of IT worldwide medical safety at Johnson & Johnson.
Intersection of technology and healthcare is just beginning
We live in a world that is becoming increasingly networked, resulting in an explosion of rich and diverse data sources.
The possibilities of what the life sciences industry may do have risen exponentially as a result of this deluge of data combined with developments in AI and machine learning.
However, a faster rate of development might bring more complexity, and the potential of digital health is only beginning to be realised.
The life sciences business is embracing technology and using it to help create fundamentally better outcomes as a result of the COVID-19 pandemic.
Our sector is fast convergent with digital healthcare, which includes categories such as telehealth and telemedicine, health information technology, and wearable devices. “$14.1 billion
in cash was spent, and 637 new digital health startups created just in 2020,” according to Sean Duffy, co-founder and CEO of Omada Health.
Collaborate to advance life sciences
The concept of collaboration and integration as a way of advancing life sciences was one of the recurrent topics brought to the forefront during Breakthrough2021.
Life sciences businesses must break through silos between departments, from medical affairs and safety to clinical development and regulatory affairs, in order to advance.
“The developments in the life sciences business are making teams more interconnected than ever,” my colleague, our Chief Product Officer Pat Jenakanandhini, expressed it beautifully.
Teams must work together more intimately, data must flow easily, and corporate procedures must be optimised in order to flourish.
Digital transformation techniques that are properly implemented can have a significant impact on medication development and patient care.”
Sanofi’s Arvind Bellur, head of safety systems and data management, emphasises the need of constructive teamwork and the use of technology to facilitate it.
“If we can simplify the way we collect data, that would be great.”